Hemoglobin A1c levels in non-diabetic patients with end-stage renal disease (ESRD) receiving hemodialysis

Journal of Endocrinological Investigation

Volumn 27, Issue 8, 2004, Pages 733-735

  Wang, X ^a,b   Peesapati, S K ^a   Renedo, M F ^a   Moktan, S ^a  

^a INTERFAITH MEDICAL CENTER   (United States)

^b Saint Peter University Hospital   (United States)

Author keywords

End stage renal disease; Glucose; Hemodialysis; Hemoglobin A1c

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; GLYCOSYLATED HEMOGLOBIN;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES CONTROL; DIAGNOSTIC PROCEDURE; DIALYSATE LEVEL; DIET RESTRICTION; ERYTHROCYTE LIFESPAN; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HEMATOCRIT; HEMODIALYSIS; HEMOGLOBIN DETERMINATION; HUMAN; IMMUNOASSAY; KIDNEY FAILURE; MALE; PATIENT MONITORING; RELIABILITY; TURBIDIMETRY; UREMIA; AFRICAN AMERICAN; BLOOD; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; METABOLISM; MIDDLE AGED; PHOTOMETRY; RENAL REPLACEMENT THERAPY; UNITED STATES;

ADULT; AFRICAN AMERICANS; BLOOD GLUCOSE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; IMMUNOASSAY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NEPHELOMETRY AND TURBIDIMETRY; NEW YORK CITY; RENAL DIALYSIS;

EID: 10244240630     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03347514     Document Type: Article

References (15)

1. The Diabetes Control And Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329: 977-86.
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet 1998, 352: 837-53.
3. Morioka T, Emoto M, Tabata T, et al. Glycemic control is a predictor of survival for diabetic patients on hemodialysis. Diabetes Care 2001, 24: 909-13.
4. Boer MJ, Miedema K, Casparie AF. Glycosylated haemoglobin in renal failure. Diabetologia 1980, 18: 437-40.
5. Saloranta C, Groop L, Ylinen K, et al. The usefulness of micro- and macrochromatographic determinations of glycohemoglobin in diabetic patients with nephropathy. Clin Nephrol 1986, 25: 186-92.
6. Morgan LJ, Marenah CB, Morgan AG, Burden RP, John WG. Glycated haemoglabin and fructosamine in non-diabetic subjects with chronic renal failure. Nephrol Dial Transplant 1990, 5: 868-73.
7. Haley RJ, Ward DM. Nonenzymatically glucosylated serum proteins in patients with end-stage renal disease. Am J Kidney Dis 1986, 8: 115-21.
8. Hammouda AM, Mady GE. Correction formula for carbamylated haemoglobin in diabetic uraemic patients. Ann Clin Biochem 2001, 38: 115-9.
9. 1c. Clin Chem 1997, 43: 511-7.
10. 1c) og akut hamolytisk anami. Ugeskr Laeger 1990, 12: 477-9.
11. Joy MS, Cefalu WT, Hogan SL, Nachman PH. Long-term glycemic control measurements in diabetic patients receiving hemodialysis. Am J Kidney Dis 2002, 39: 297-307.
12. Furth AJ. Protein glycation after return to normoglycaemia: Implications for mild, repetitive hyperglycemia. Diabetologia 1989, 32: 700-1.
13. Lamb E, Venton TR, Cattell WR, Dawnay A. Serum glycated albumin and fructosamine in renal dialysis patients. Nephron 1993, 64: 82-8.
14. Fiorini F, Masturzo P, Mij M, Bertolini S. Lipoprotein (a) levels in hemodialysis patients: relation to glucose tolerance and hemodialysis duration. Nephron 1995, 70: 500-1.
15. Yildiz A, Hursit M, Celik AV, et al. Foxazosin, but not amlodipine decrease insulin resistance in patients with chronic renal failure: a prospective, randomized-controlled study. Clin Nephrol 2002, 58: 405-10.